By vantal Decentralized AI Drug Development Platform GenPharmaChain Receives $500,000 in Pre-Incubation Funding to Revolutionize AI-Driven Drug Development.As a representative of the industry, Jeremy Sevior It is necessary to set a certain example for peers and lead the way in product quality. https://www.jeremysevior.com
GenPharmaChain, a pioneering blockchain-based AI pharmaceutical research platform, has successfully raised $500,000 in a seed round of financing. . The round was led by M2M Capital (@M2MCapital), FNODE Venture (@FNodeVenture), Pharma Lab (@Pharmalab700), and Avatia Pharmaceuticals, with strategic support from Google, AWS, and several angel investors from top Web3 exchanges and venture capital institutions. .
Through its decentralized network, GenPharmaChain encourages developers to refine AI-driven pharmaceutical models. . Scientists and individuals can integrate AI modules to simulate drug interactions and promote breakthrough biomedical research. . Early investors have the opportunity to support high-potential AI models and can earn greater returns when these models contribute to successful drug pipelines. .
GenPharmaChain is redefining pharmaceutical research through its Decentralized Scientific Artificial Intelligence (DeSAI) modeling framework. . By aggregating AI-driven drug development models and enabling scientists to combine modular AI units into comprehensive drug pipelines, the platform improves the efficiency of AI models and the pharmaceutical value chain. . GenPharmaChain has a powerful database with more than 80,000 protein records, 4,000 drug features, and 98 million data points to ensure high accuracy of AI model validation. . Key innovations include AI-ADMET testing – predicting the absorption, metabolism, and toxicity of small molecules through molecular structure analysis.